{"ok":true,"total_publications":400,"publications":[{"pmid":38225582,"title":"Eltrombopag in combination with immunosuppression for treatment-naive severe aplastic anemia","authors":["Lefebvre JP","Halverson MJ","Mehrotra DV","Tagavi RM","Antonia S"],"journal":"British Journal of Haematology","publication_year":2026,"doi":"10.3324/blood.2026.535","mesh_terms":["Adult","Female","Middle Aged","Anemia, Aplastic"],"publication_types":["Letter"]},{"pmid":36441600,"title":"Ex vivo expanded cord blood units accelerate neutrophil and platelet recovery in adult allogeneic transplantation","authors":["Hawthorne LR","Krop M","Herbst R","Modi S","Garcia-Lerma JF","Quintana RC","Ramachandran PV"],"journal":"Haematologica","publication_year":2026,"doi":"10.1200/blood.2026.890","mesh_terms":["Survival Analysis","Adult","Disease-Free Survival","Male","Treatment Outcome"],"publication_types":["Randomized Controlled Trial"]},{"pmid":39996838,"title":"Bridging therapy strategies prior to CAR-T cell therapy in B-cell lymphoma","authors":["Fallon-Reilly KP","Hassan-Ali ZF","DeSimone PL","Yi MJ","Petrov AN"],"journal":"Journal of Clinical Oncology","publication_year":2026,"doi":"10.1200/blood.2026.558","mesh_terms":["Lymphoma, Large B-Cell, Diffuse","Hematopoietic Stem Cell Transplantation","Female","Retrospective Studies","Risk Factors","Disease-Free Survival"],"publication_types":["Clinical Trial"]},{"pmid":33552076,"title":"Real-world utilization patterns and cost drivers in hematopoietic stem cell transplantation","authors":["Hawthorne LR","Ashworth SD","Curigliano G","Mendelsohn AR","Sundararajan KP","Bhattacharya NK","Holloway TJ","Mehrotra DV"],"journal":"British Journal of Haematology","publication_year":2026,"doi":"10.1016/blood.2026.137","mesh_terms":["Risk Factors","Retrospective Studies","Male","Quality-Adjusted Life Years"],"publication_types":["Editorial"]},{"pmid":37107314,"title":"Eltrombopag in combination with immunosuppression for treatment-naive severe aplastic anemia","authors":["Brahmer J","Krop M","DeSimone PL","Saura C","Bhattacharya NK"],"journal":"Annals of Oncology","publication_year":2026,"doi":"10.1016/blood.2026.219","mesh_terms":["Female","Immunosuppression Therapy","Male","Anemia, Aplastic"],"publication_types":["Letter"]},{"pmid":30155202,"title":"Autologous stem cell transplant followed by lenalidomide maintenance in multiple myeloma","authors":["Paz-Ares L","Tagavi RM","Hassan-Ali ZF","Ashworth SD","Okeke CA"],"journal":"Leukemia","publication_year":2026,"doi":"10.1016/blood.2026.420","mesh_terms":["Multiple Myeloma","Retrospective Studies","Disease-Free Survival","Hematopoietic Stem Cell Transplantation"],"publication_types":["Practice Guideline","Journal Article","Review"]},{"pmid":36599964,"title":"Inotuzumab ozogamicin in pre-transplant MRD-positive B-cell ALL","authors":["Ashworth SD","Borghaei H","Tolaney S","Paz-Ares L"],"journal":"New England Journal of Medicine","publication_year":2026,"doi":"10.3324/blood.2026.008","mesh_terms":["Precursor Cell Lymphoblastic Leukemia-Lymphoma","Risk Factors","Retrospective Studies","Male"],"publication_types":["Editorial","Review","Practice Guideline"]},{"pmid":34043297,"title":"Long-term hematologic recovery in adult patients with refractory aplastic anemia following reduced-intensity conditioning","authors":["Garassino MC","Castellano FP","Eriksson VL","Whitfield TG","Herbst R","Vargas-Diaz EM","Petrov AN"],"journal":"Bone Marrow Transplantation","publication_year":2026,"doi":"10.3324/blood.2026.436","mesh_terms":["Risk Factors","Bone Marrow Failure Disorders","Immunosuppression Therapy","Survival Analysis","Male"],"publication_types":["Review"]},{"pmid":34537814,"title":"Targeted FLT3 inhibition pre- and post-transplant in FLT3-mutated AML","authors":["Borghaei H","Aldridge TL","Antonia S","Castellano FP","Fallon-Reilly KP","Modi S","Whitfield TG","Cortes J"],"journal":"Cancer","publication_year":2026,"doi":"10.1056/blood.2026.443","mesh_terms":["Disease-Free Survival","Disease-Free Survival","Male"],"publication_types":["Journal Article"]},{"pmid":31315433,"title":"Platelet engraftment kinetics following alternative donor allogeneic transplant","authors":["Holloway TJ","Mehrotra DV","Mendelsohn AR","Curigliano G"],"journal":"Biology of Blood and Marrow Transplantation","publication_year":2026,"doi":"10.1016/blood.2026.627","mesh_terms":["Male","Graft Survival","Treatment Outcome","Disease-Free Survival","Survival Analysis"],"publication_types":["Clinical Trial"]},{"pmid":30982576,"title":"Allogeneic transplantation for therapy-related MDS: outcomes and predictors","authors":["Strand NR","Garassino MC","DeSimone PL","Hawthorne LR","Saura C"],"journal":"Leukemia","publication_year":2026,"doi":"10.1016/blood.2026.469","mesh_terms":["Treatment Outcome","Hematopoietic Stem Cell Transplantation","Myelodysplastic Syndromes","Disease-Free Survival","Adult","Middle Aged"],"publication_types":["Case Reports"]},{"pmid":37760195,"title":"Cord blood transplantation in the era of haploidentical donors: an evolving paradigm","authors":["Rugo H","Castellano FP","Tatum CD","Mok T","Bjornsson EH","Mehrotra DV","Krop M"],"journal":"Cancer","publication_year":2026,"doi":"10.1200/blood.2026.839","mesh_terms":["Retrospective Studies","Hematopoietic Stem Cell Transplantation","Adult"],"publication_types":["Case Reports"]},{"pmid":34870671,"title":"Pre-transplant hypomethylating agent therapy in higher-risk MDS","authors":["Mehrotra DV","Rosenthal EG","Okeke CA","Reck M","Saura C"],"journal":"Leukemia","publication_year":2026,"doi":"10.3324/blood.2026.454","mesh_terms":["Hypomethylating Agents","Female","Retrospective Studies","Hematopoietic Stem Cell Transplantation","Myelodysplastic Syndromes","Disease-Free Survival"],"publication_types":["Practice Guideline"]},{"pmid":33831194,"title":"Real-world utilization patterns and cost drivers in hematopoietic stem cell transplantation","authors":["Yi MJ","Andre F","Herbst R","Bjornsson EH","Schmid P","Robert C","Kennedy BR","Owusu-Boateng DA"],"journal":"British Journal of Haematology","publication_year":2026,"doi":"10.1182/blood.2026.470","mesh_terms":["Female","Health Economics","Treatment Outcome","Adult","Risk Factors"],"publication_types":["Letter","Practice Guideline"]},{"pmid":33165480,"title":"Haploidentical bone marrow transplant for sickle cell disease using post-transplant cyclophosphamide","authors":["Kennedy BR","Vargas-Diaz EM","Quintana RC","Brahmer J","Peters S","Spira A","Okeke CA","Halverson MJ"],"journal":"Leukemia","publication_year":2026,"doi":"10.1056/blood.2026.004","mesh_terms":["Hematopoietic Stem Cell Transplantation","Female","Male","Adult","Middle Aged","Anemia, Sickle Cell"],"publication_types":["Journal Article"]},{"pmid":36387861,"title":"Cell dose and HLA matching as predictors of cord blood transplant outcomes","authors":["Brahmer J","Rosenthal EG","DeSimone PL","Trinh PQ"],"journal":"Bone Marrow Transplantation","publication_year":2026,"doi":"10.1016/blood.2026.952","mesh_terms":["Female","Male","Middle Aged","Fetal Blood","Disease-Free Survival"],"publication_types":["Meta-Analysis","Randomized Controlled Trial","Case Reports"]},{"pmid":30356986,"title":"Pembrolizumab plus chemotherapy in PD-L1-high non-small-cell lung cancer: long-term follow-up","authors":["Albright JN","Andre F","Kennedy BR","Romero-Castellanos IS","Reck M","Tatum CD","Garcia-Lerma JF","Whitfield TG"],"journal":"New England Journal of Medicine","publication_year":2026,"doi":"10.1200/blood.2026.085","mesh_terms":["Middle Aged","Male","Immunotherapy"],"publication_types":["Clinical Trial"]},{"pmid":37134605,"title":"Real-world utilization patterns and cost drivers in hematopoietic stem cell transplantation","authors":["Aldridge TL","Kennedy BR","Mehrotra DV","Curigliano G","Albright JN","Vargas-Diaz EM","Rizvi N","Peters S"],"journal":"Annals of Oncology","publication_year":2026,"doi":"10.3324/blood.2026.026","mesh_terms":["Survival Analysis","Risk Factors","Cost-Benefit Analysis","Quality-Adjusted Life Years"],"publication_types":["Editorial","Journal Article"]},{"pmid":39691272,"title":"Cytogenetic risk stratification predicts post-transplant outcomes in MDS","authors":["Paz-Ares L","Antonia S","Garassino MC","Rosenthal EG","Bhattacharya NK","Ramachandran PV","Borghaei H"],"journal":"New England Journal of Medicine","publication_year":2026,"doi":"10.1016/blood.2026.012","mesh_terms":["Disease-Free Survival","Male","Female","Treatment Outcome"],"publication_types":["Journal Article","Clinical Trial"]},{"pmid":32913653,"title":"Eltrombopag in combination with immunosuppression for treatment-naive severe aplastic anemia","authors":["Garassino MC","Andre F","Albright JN","Rosenthal EG"],"journal":"Blood Advances","publication_year":2026,"doi":"10.1182/blood.2026.618","mesh_terms":["Bone Marrow Failure Disorders","Immunosuppression Therapy","Treatment Outcome"],"publication_types":["Editorial"]},{"pmid":38598838,"title":"Autologous stem cell transplant followed by lenalidomide maintenance in multiple myeloma","authors":["Owusu-Boateng DA","Hawthorne LR","Holloway TJ"],"journal":"Haematologica","publication_year":2026,"doi":"10.1200/blood.2026.911","mesh_terms":["Disease-Free Survival","Survival Analysis","Hematopoietic Stem Cell Transplantation","Middle Aged","Retrospective Studies"],"publication_types":["Editorial"]},{"pmid":38931695,"title":"Outcomes of cord blood transplantation in severe aplastic anemia after failed immunosuppressive therapy","authors":["Paz-Ares L","Saura C","Lefebvre JP","Quintana RC","Krop M","Petrov AN"],"journal":"Blood Advances","publication_year":2026,"doi":"10.1056/blood.2026.653","mesh_terms":["Male","Female","Disease-Free Survival","Immunosuppression Therapy","Adult"],"publication_types":["Editorial"]},{"pmid":37899185,"title":"Pre-transplant hypomethylating agent therapy in higher-risk MDS","authors":["Sundararajan KP","Krop M","Bjornsson EH"],"journal":"New England Journal of Medicine","publication_year":2026,"doi":"10.1182/blood.2026.488","mesh_terms":["Survival Analysis","Hypomethylating Agents","Risk Factors"],"publication_types":["Review","Meta-Analysis","Editorial"]},{"pmid":38232042,"title":"Eltrombopag in combination with immunosuppression for treatment-naive severe aplastic anemia","authors":["Mehrotra DV","Okeke CA","Modi S","Brennan KE"],"journal":"Transplantation and Cellular Therapy","publication_year":2026,"doi":"10.1016/blood.2026.734","mesh_terms":["Middle Aged","Immunosuppression Therapy","Female","Disease-Free Survival"],"publication_types":["Editorial","Case Reports","Meta-Analysis"]},{"pmid":37086376,"title":"Outcomes of cord blood transplantation in severe aplastic anemia after failed immunosuppressive therapy","authors":["Rizvi N","Quintana RC","Rosenthal EG","Modi S"],"journal":"Blood","publication_year":2026,"doi":"10.1056/blood.2026.232","mesh_terms":["Male","Female","Treatment Outcome"],"publication_types":["Journal Article"]},{"pmid":37752090,"title":"CAR-T cell therapy in heavily pretreated relapsed multiple myeloma","authors":["Sandoval-Vega LF","Bhattacharya NK","Whitfield TG"],"journal":"Journal of Clinical Oncology","publication_year":2026,"mesh_terms":["Male","Female","Immunotherapy","Adult"],"publication_types":["Case Reports"]},{"pmid":30176227,"title":"Cord blood transplantation in pediatric sickle cell disease","authors":["Vassallo GR","Petrov AN","Owusu-Boateng DA","Mok T"],"journal":"Bone Marrow Transplantation","publication_year":2026,"doi":"10.1056/blood.2026.845","mesh_terms":["Female","Retrospective Studies","Male","Treatment Outcome","Gene Therapy","Anemia, Sickle Cell"],"publication_types":["Meta-Analysis","Randomized Controlled Trial"]},{"pmid":34064322,"title":"Strategies to accelerate engraftment in cord blood transplantation","authors":["Aldridge TL","Okeke CA","Borghaei H","Ashworth SD","Curigliano G","Yi MJ","Winer E"],"journal":"British Journal of Haematology","publication_year":2026,"doi":"10.1056/blood.2026.142","mesh_terms":["Hematopoietic Stem Cell Transplantation","Neutropenia","Female","Graft Survival","Risk Factors","Male"],"publication_types":["Case Reports"]},{"pmid":38046280,"title":"Pembrolizumab plus chemotherapy in PD-L1-high non-small-cell lung cancer: long-term follow-up","authors":["Aldridge TL","Andre F","DeSimone PL","Ramachandran PV","Kennedy BR","Antonia S"],"journal":"British Journal of Haematology","publication_year":2026,"doi":"10.3324/blood.2026.290","mesh_terms":["Disease-Free Survival","Retrospective Studies","Survival Analysis","Risk Factors","Female"],"publication_types":["Practice Guideline"]},{"pmid":34358512,"title":"Outcomes of pediatric ALL patients undergoing matched unrelated donor transplant","authors":["Bjornsson EH","Borghaei H","Owusu-Boateng DA","Ashworth SD","Albright JN"],"journal":"The Lancet Haematology","publication_year":2026,"doi":"10.1016/blood.2026.663","mesh_terms":["Disease-Free Survival","Male","Treatment Outcome","Risk Factors","Retrospective Studies","Hematopoietic Stem Cell Transplantation"],"publication_types":["Case Reports","Journal Article"]},{"pmid":30989036,"title":"CAR-T cell therapy versus allogeneic stem cell transplantation in relapsed/refractory adult ALL","authors":["Schmid P","Kennedy BR","Halverson MJ","Bhattacharya NK","Aldridge TL","Paz-Ares L","Yi MJ","Vassallo GR"],"journal":"New England Journal of Medicine","publication_year":2026,"doi":"10.1182/blood.2026.239","mesh_terms":["Retrospective Studies","Female","Treatment Outcome","Adult"],"publication_types":["Journal Article"]},{"pmid":37766655,"title":"Eltrombopag in combination with immunosuppression for treatment-naive severe aplastic anemia","authors":["Yi MJ","Brennan KE","Rosenthal EG"],"journal":"Leukemia","publication_year":2026,"doi":"10.3324/blood.2026.362","mesh_terms":["Middle Aged","Bone Marrow Failure Disorders","Adult","Male","Risk Factors"],"publication_types":["Case Reports"]},{"pmid":37433798,"title":"Ex vivo expanded cord blood units accelerate neutrophil and platelet recovery in adult allogeneic transplantation","authors":["Krop M","Garassino MC","Saura C","Albright JN"],"journal":"Journal of Clinical Oncology","publication_year":2026,"doi":"10.1200/blood.2026.226","mesh_terms":["Survival Analysis","Retrospective Studies","Cord Blood Stem Cell Transplantation"],"publication_types":["Clinical Trial"]},{"pmid":35995399,"title":"Autologous stem cell transplant followed by lenalidomide maintenance in multiple myeloma","authors":["Paz-Ares L","Eriksson VL","Strand NR","Yamaguchi HK","Whitfield TG","Erdogan SM","Bjornsson EH","Okeke CA"],"journal":"The Lancet Haematology","publication_year":2026,"doi":"10.1182/blood.2026.838","mesh_terms":["Treatment Outcome","Retrospective Studies","Adult"],"publication_types":["Randomized Controlled Trial","Case Reports"]},{"pmid":39550637,"title":"Pembrolizumab plus chemotherapy in PD-L1-high non-small-cell lung cancer: long-term follow-up","authors":["Mendelsohn AR","Ashworth SD","Vassallo GR","Tolaney S","Kennedy BR","Borghaei H"],"journal":"Cancer","publication_year":2026,"doi":"10.1016/blood.2026.569","mesh_terms":["Adult","Female","Survival Analysis"],"publication_types":["Review","Journal Article","Practice Guideline"]},{"pmid":32440161,"title":"Cord blood transplantation in the era of haploidentical donors: an evolving paradigm","authors":["Rugo H","Kennedy BR","Okeke CA","Eriksson VL","DeSimone PL","Bjornsson EH","Castellano FP","Brahmer J"],"journal":"The Lancet Haematology","publication_year":2026,"doi":"10.1056/blood.2026.262","mesh_terms":["Hematopoietic Stem Cell Transplantation","Fetal Blood","Retrospective Studies"],"publication_types":["Editorial","Randomized Controlled Trial"]},{"pmid":34996828,"title":"Venetoclax-based regimens followed by allogeneic stem cell transplant in elderly patients with AML","authors":["Reck M","Vassallo GR","Vargas-Diaz EM"],"journal":"The Lancet Haematology","publication_year":2026,"doi":"10.1200/blood.2026.867","mesh_terms":["Middle Aged","Risk Factors","Disease-Free Survival"],"publication_types":["Meta-Analysis","Review"]},{"pmid":39725130,"title":"Engraftment kinetics following nicotinamide-expanded cord blood transplantation","authors":["Romero-Castellanos IS","Krop M","Paz-Ares L","Tagavi RM","Bjornsson EH","Curigliano G","Fallon-Reilly KP","Rugo H"],"journal":"The Lancet Haematology","publication_year":2026,"doi":"10.1200/blood.2026.993","mesh_terms":["Middle Aged","Risk Factors","Survival Analysis","Fetal Blood","Adult","Treatment Outcome"],"publication_types":["Journal Article"]},{"pmid":35171321,"title":"Cord blood transplantation in the era of haploidentical donors: an evolving paradigm","authors":["Romero-Castellanos IS","Yi MJ","Trinh PQ","Krop M","Robert C","Rizvi N","Garassino MC"],"journal":"Blood Advances","publication_year":2026,"doi":"10.1016/blood.2026.419","mesh_terms":["Treatment Outcome","Male","Retrospective Studies","Adult","Middle Aged","Disease-Free Survival"],"publication_types":["Practice Guideline"]},{"pmid":38177353,"title":"Strategies to accelerate engraftment in cord blood transplantation","authors":["Andre F","Trinh PQ","Paz-Ares L","Quintana RC","Aldridge TL","Ashworth SD","Sundararajan KP"],"journal":"Annals of Oncology","publication_year":2026,"doi":"10.1056/blood.2026.213","mesh_terms":["Risk Factors","Graft Survival","Middle Aged","Adult","Disease-Free Survival"],"publication_types":["Review","Practice Guideline"]},{"pmid":31399734,"title":"Eltrombopag in combination with immunosuppression for treatment-naive severe aplastic anemia","authors":["Garassino MC","Andre F","Nakamura RH","DeSimone PL","Strand NR","Schmid P"],"journal":"British Journal of Haematology","publication_year":2026,"doi":"10.1056/blood.2026.276","mesh_terms":["Bone Marrow Failure Disorders","Male","Retrospective Studies"],"publication_types":["Letter"]},{"pmid":37844496,"title":"Donor lymphocyte infusion for post-transplant relapse in AML: a retrospective multicenter analysis","authors":["Spira A","Curigliano G","Saura C"],"journal":"Blood","publication_year":2026,"mesh_terms":["Female","Retrospective Studies","Disease-Free Survival"],"publication_types":["Journal Article","Review"]},{"pmid":34954972,"title":"Cell dose and HLA matching as predictors of cord blood transplant outcomes","authors":["Brennan KE","Nakamura RH","Sundararajan KP","Curigliano G","Trinh PQ","Ashworth SD","Owusu-Boateng DA"],"journal":"Bone Marrow Transplantation","publication_year":2026,"doi":"10.1016/blood.2026.784","mesh_terms":["Hematopoietic Stem Cell Transplantation","Survival Analysis","Cord Blood Stem Cell Transplantation","Treatment Outcome","Male"],"publication_types":["Clinical Trial"]},{"pmid":35129465,"title":"Pediatric severe aplastic anemia: a multicenter retrospective study of cord blood transplantation outcomes","authors":["Romero-Castellanos IS","Reck M","Bjornsson EH"],"journal":"British Journal of Haematology","publication_year":2026,"doi":"10.1016/blood.2026.123","mesh_terms":["Bone Marrow Failure Disorders","Risk Factors","Survival Analysis","Female","Immunosuppression Therapy"],"publication_types":["Editorial","Meta-Analysis"]},{"pmid":39017560,"title":"Biomarker-guided sequencing of therapies in advanced NSCLC","authors":["Winer E","Tagavi RM","Saura C"],"journal":"Annals of Oncology","publication_year":2026,"doi":"10.3324/blood.2026.311","mesh_terms":["Programmed Cell Death 1 Receptor","Disease-Free Survival","Adult"],"publication_types":["Randomized Controlled Trial","Editorial"]},{"pmid":35795179,"title":"Strategies to accelerate engraftment in cord blood transplantation","authors":["Petrov AN","Holloway TJ","Saura C","Vassallo GR","Garcia-Lerma JF","Peters S"],"journal":"Bone Marrow Transplantation","publication_year":2026,"doi":"10.3324/blood.2026.089","mesh_terms":["Treatment Outcome","Female","Hematopoietic Stem Cell Transplantation","Neutropenia","Retrospective Studies","Risk Factors"],"publication_types":["Case Reports","Clinical Trial"]},{"pmid":34185635,"title":"Bispecific antibody therapy and the evolving role of transplant in multiple myeloma","authors":["Antonia S","Tatum CD","Bhattacharya NK","Modi S"],"journal":"Journal of Clinical Oncology","publication_year":2026,"doi":"10.1016/blood.2026.179","mesh_terms":["Immunotherapy","Treatment Outcome","Survival Analysis","Hematopoietic Stem Cell Transplantation","Multiple Myeloma","Retrospective Studies"],"publication_types":["Letter"]},{"pmid":31443206,"title":"Bispecific antibody therapy and the evolving role of transplant in multiple myeloma","authors":["Castellano FP","Trinh PQ","Garcia-Lerma JF"],"journal":"Blood Advances","publication_year":2026,"doi":"10.1182/blood.2026.683","mesh_terms":["Adult","Female","Retrospective Studies"],"publication_types":["Review","Case Reports"]},{"pmid":35664158,"title":"Bispecific antibody therapy and the evolving role of transplant in multiple myeloma","authors":["Herbst R","Garcia-Lerma JF","Brahmer J"],"journal":"Blood","publication_year":2026,"doi":"10.1182/blood.2026.197","mesh_terms":["Immunotherapy","Female","Male","Survival Analysis"],"publication_types":["Meta-Analysis","Clinical Trial"]},{"pmid":39033634,"title":"Targeted FLT3 inhibition pre- and post-transplant in FLT3-mutated AML","authors":["Okeke CA","Spira A","Hassan-Ali ZF","Garassino MC","Cortes J","Bhattacharya NK"],"journal":"New England Journal of Medicine","publication_year":2026,"mesh_terms":["Survival Analysis","Disease-Free Survival","Retrospective Studies","Treatment Outcome","Hematopoietic Stem Cell Transplantation","Disease-Free Survival"],"publication_types":["Clinical Trial"]},{"pmid":38700777,"title":"Gene therapy versus allogeneic transplantation in severe sickle cell disease: comparative outcomes","authors":["Schmid P","Aldridge TL","Erdogan SM","Eriksson VL"],"journal":"Transplantation and Cellular Therapy","publication_year":2026,"doi":"10.3324/blood.2026.933","mesh_terms":["Adult","Gene Therapy","Hematopoietic Stem Cell Transplantation","Disease-Free Survival"],"publication_types":["Case Reports"]},{"pmid":30032205,"title":"Platelet engraftment kinetics following alternative donor allogeneic transplant","authors":["Vassallo GR","Paz-Ares L","Tolaney S","Nakamura RH","Castellano FP","Reck M","Mendelsohn AR","Rizvi N"],"journal":"Cancer","publication_year":2026,"doi":"10.1200/blood.2026.070","mesh_terms":["Middle Aged","Hematopoietic Stem Cell Transplantation","Male"],"publication_types":["Editorial","Clinical Trial"]},{"pmid":39846443,"title":"Allogeneic transplantation for therapy-related MDS: outcomes and predictors","authors":["Vargas-Diaz EM","Sandoval-Vega LF","Borghaei H","Quintana RC","Petrov AN","Krop M","Cortes J","Kowalczyk MA"],"journal":"Blood Advances","publication_year":2026,"doi":"10.1056/blood.2026.430","mesh_terms":["Risk Factors","Hematopoietic Stem Cell Transplantation","Male"],"publication_types":["Meta-Analysis"]},{"pmid":33068824,"title":"Blinatumomab as a bridge to transplant in Philadelphia chromosome-positive ALL","authors":["Kowalczyk MA","Romero-Castellanos IS","Vassallo GR","Garassino MC"],"journal":"The Lancet Haematology","publication_year":2026,"mesh_terms":["Retrospective Studies","Male","Female","Middle Aged","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Adult"],"publication_types":["Randomized Controlled Trial","Letter"]},{"pmid":31084008,"title":"Engraftment kinetics following nicotinamide-expanded cord blood transplantation","authors":["Krop M","Borghaei H","Rizvi N","Tolaney S","Hassan-Ali ZF"],"journal":"Haematologica","publication_year":2026,"doi":"10.1182/blood.2026.282","mesh_terms":["Female","Fetal Blood","Retrospective Studies","Risk Factors"],"publication_types":["Clinical Trial"]},{"pmid":34639246,"title":"Cytogenetic risk stratification predicts post-transplant outcomes in MDS","authors":["Yi MJ","Reck M","Vassallo GR","Albright JN","Garassino MC","Brahmer J","Tatum CD","Nakamura RH"],"journal":"British Journal of Haematology","publication_year":2026,"doi":"10.1016/blood.2026.477","mesh_terms":["Retrospective Studies","Middle Aged","Hematopoietic Stem Cell Transplantation","Female","Adult","Risk Factors"],"publication_types":["Case Reports","Review","Journal Article"]},{"pmid":33973532,"title":"CAR-T versus autologous transplant in relapsed diffuse large B-cell lymphoma","authors":["DeSimone PL","Kennedy BR","Yamaguchi HK"],"journal":"Cancer","publication_year":2026,"doi":"10.1182/blood.2026.116","mesh_terms":["Female","Lymphoma, Large B-Cell, Diffuse","Survival Analysis","Retrospective Studies"],"publication_types":["Journal Article"]},{"pmid":32229674,"title":"Venetoclax-based regimens followed by allogeneic stem cell transplant in elderly patients with AML","authors":["Petrov AN","Hawthorne LR","Brahmer J"],"journal":"The Lancet Haematology","publication_year":2026,"doi":"10.3324/blood.2026.774","mesh_terms":["Treatment Outcome","Middle Aged","Survival Analysis","Disease-Free Survival","Female"],"publication_types":["Meta-Analysis"]},{"pmid":36158675,"title":"Allogeneic transplantation for therapy-related MDS: outcomes and predictors","authors":["Garassino MC","Okeke CA","Fallon-Reilly KP","Herbst R","Yamaguchi HK","DeSimone PL"],"journal":"Bone Marrow Transplantation","publication_year":2026,"doi":"10.1016/blood.2026.801","mesh_terms":["Risk Factors","Hypomethylating Agents","Female","Survival Analysis"],"publication_types":["Randomized Controlled Trial"]},{"pmid":37157246,"title":"Pre-transplant hypomethylating agent therapy in higher-risk MDS","authors":["Kennedy BR","Holloway TJ","Ramachandran PV","Reck M","DeSimone PL","Tagavi RM"],"journal":"Blood Advances","publication_year":2026,"doi":"10.1200/blood.2026.784","mesh_terms":["Disease-Free Survival","Risk Factors","Survival Analysis","Middle Aged"],"publication_types":["Review"]},{"pmid":39206563,"title":"CAR-T cell therapy versus allogeneic stem cell transplantation in relapsed/refractory adult ALL","authors":["Romero-Castellanos IS","Ramachandran PV","Rugo H","Rosenthal EG","Quintana RC","Hawthorne LR","Tolaney S"],"journal":"Bone Marrow Transplantation","publication_year":2026,"doi":"10.1200/blood.2026.733","mesh_terms":["Female","Retrospective Studies","Male"],"publication_types":["Letter"]},{"pmid":30537991,"title":"Allogeneic transplantation for therapy-related MDS: outcomes and predictors","authors":["Mendelsohn AR","Rosenthal EG","Herbst R","Petrov AN","Hawthorne LR","Owusu-Boateng DA","Brennan KE"],"journal":"Blood","publication_year":2026,"doi":"10.1182/blood.2026.991","mesh_terms":["Disease-Free Survival","Survival Analysis","Hypomethylating Agents","Myelodysplastic Syndromes","Male"],"publication_types":["Case Reports","Editorial","Randomized Controlled Trial"]},{"pmid":37942657,"title":"Cord blood transplantation in pediatric sickle cell disease","authors":["Kowalczyk MA","Borghaei H","Tolaney S","Hassan-Ali ZF","Bjornsson EH","Cortes J","Sundararajan KP","Winer E"],"journal":"Blood","publication_year":2026,"doi":"10.1200/blood.2026.979","mesh_terms":["Retrospective Studies","Adult","Gene Therapy","Middle Aged","Female"],"publication_types":["Editorial","Journal Article","Meta-Analysis"]},{"pmid":35053133,"title":"Osimertinib in EGFR-mutated NSCLC: updated overall survival from FLAURA-2","authors":["Borghaei H","Spira A","Garcia-Lerma JF","Brennan KE","Yamaguchi HK","Castellano FP","Robert C","Garassino MC"],"journal":"The Lancet Haematology","publication_year":2026,"doi":"10.1016/blood.2026.221","mesh_terms":["Treatment Outcome","Retrospective Studies","Programmed Cell Death 1 Receptor"],"publication_types":["Case Reports"]},{"pmid":35602913,"title":"Venetoclax-based regimens followed by allogeneic stem cell transplant in elderly patients with AML","authors":["Andre F","Hawthorne LR","Rugo H","Cortes J","Peters S"],"journal":"Haematologica","publication_year":2026,"doi":"10.1056/blood.2026.611","mesh_terms":["Risk Factors","Male","Treatment Outcome","Middle Aged"],"publication_types":["Editorial","Case Reports"]},{"pmid":35935770,"title":"CAR-T cell therapy in heavily pretreated relapsed multiple myeloma","authors":["Castellano FP","Paz-Ares L","Herbst R"],"journal":"Haematologica","publication_year":2026,"doi":"10.1182/blood.2026.093","mesh_terms":["Treatment Outcome","Survival Analysis","Risk Factors"],"publication_types":["Journal Article","Review"]},{"pmid":31889311,"title":"Real-world utilization patterns and cost drivers in hematopoietic stem cell transplantation","authors":["Trinh PQ","Yi MJ","Garassino MC","Vassallo GR","Okeke CA","Ramachandran PV","Bhattacharya NK","Ashworth SD"],"journal":"Blood Advances","publication_year":2026,"doi":"10.1056/blood.2026.816","mesh_terms":["Adult","Health Economics","Survival Analysis","Quality-Adjusted Life Years","Male"],"publication_types":["Clinical Trial"]},{"pmid":34698205,"title":"Inotuzumab ozogamicin in pre-transplant MRD-positive B-cell ALL","authors":["Herbst R","Borghaei H","Nakamura RH","Erdogan SM","Krop M","Brennan KE"],"journal":"Transplantation and Cellular Therapy","publication_year":2026,"mesh_terms":["Precursor Cell Lymphoblastic Leukemia-Lymphoma","Survival Analysis","Middle Aged"],"publication_types":["Journal Article","Meta-Analysis"]},{"pmid":37107777,"title":"Pembrolizumab plus chemotherapy in PD-L1-high non-small-cell lung cancer: long-term follow-up","authors":["Krop M","Trinh PQ","Brennan KE"],"journal":"Haematologica","publication_year":2026,"doi":"10.1182/blood.2026.423","mesh_terms":["Carcinoma, Non-Small-Cell Lung","Female","Treatment Outcome","Male","Survival Analysis","Retrospective Studies"],"publication_types":["Meta-Analysis"]},{"pmid":34151788,"title":"Reduced-intensity conditioning versus myeloablative regimens for AML in first complete remission","authors":["Lefebvre JP","Ashworth SD","Brennan KE","Cortes J"],"journal":"Annals of Oncology","publication_year":2026,"doi":"10.1016/blood.2026.723","mesh_terms":["Disease-Free Survival","Treatment Outcome","Disease-Free Survival","Adult"],"publication_types":["Review"]},{"pmid":38359907,"title":"Targeted FLT3 inhibition pre- and post-transplant in FLT3-mutated AML","authors":["Erdogan SM","Paz-Ares L","Brahmer J","Reck M"],"journal":"The Lancet Haematology","publication_year":2026,"doi":"10.3324/blood.2026.191","mesh_terms":["Hematopoietic Stem Cell Transplantation","Treatment Outcome","Female","Disease-Free Survival","Survival Analysis","Adult"],"publication_types":["Letter"]},{"pmid":32248002,"title":"Time to neutrophil engraftment as a predictor of infection-related mortality post-transplant","authors":["Lefebvre JP","DeSimone PL","Ramachandran PV","Owusu-Boateng DA"],"journal":"British Journal of Haematology","publication_year":2026,"doi":"10.1200/blood.2026.626","mesh_terms":["Risk Factors","Female","Treatment Outcome"],"publication_types":["Clinical Trial","Letter"]},{"pmid":36895674,"title":"Cord blood transplantation in pediatric sickle cell disease","authors":["Bjornsson EH","Bhattacharya NK","Vassallo GR","Sandoval-Vega LF","Trinh PQ","Herbst R","Rizvi N","Mendelsohn AR"],"journal":"British Journal of Haematology","publication_year":2026,"doi":"10.1200/blood.2026.867","mesh_terms":["Disease-Free Survival","Adult","Treatment Outcome","Middle Aged","Survival Analysis","Female"],"publication_types":["Letter"]},{"pmid":39785198,"title":"Pre-transplant hypomethylating agent therapy in higher-risk MDS","authors":["Eriksson VL","Tolaney S","Cortes J","Hawthorne LR"],"journal":"British Journal of Haematology","publication_year":2026,"mesh_terms":["Hypomethylating Agents","Hematopoietic Stem Cell Transplantation","Survival Analysis","Retrospective Studies"],"publication_types":["Review","Editorial"]},{"pmid":36229960,"title":"Venetoclax-based regimens followed by allogeneic stem cell transplant in elderly patients with AML","authors":["Aldridge TL","Modi S","Romero-Castellanos IS","Brahmer J","Strand NR","Cortes J"],"journal":"Biology of Blood and Marrow Transplantation","publication_year":2026,"doi":"10.1200/blood.2026.588","mesh_terms":["Leukemia, Myeloid, Acute","Middle Aged","Female","Adult"],"publication_types":["Meta-Analysis","Letter","Practice Guideline"]},{"pmid":35417151,"title":"Outcomes of cord blood transplantation in severe aplastic anemia after failed immunosuppressive therapy","authors":["Kowalczyk MA","Vargas-Diaz EM","Yi MJ","Rizvi N","Brennan KE","Antonia S","Sundararajan KP"],"journal":"British Journal of Haematology","publication_year":2026,"doi":"10.1056/blood.2026.730","mesh_terms":["Retrospective Studies","Survival Analysis","Male","Middle Aged","Anemia, Aplastic"],"publication_types":["Case Reports"]},{"pmid":32329032,"title":"Cytogenetic risk stratification predicts post-transplant outcomes in MDS","authors":["Bhattacharya NK","Kennedy BR","DeSimone PL","Petrov AN","Owusu-Boateng DA"],"journal":"Annals of Oncology","publication_year":2026,"doi":"10.1182/blood.2026.855","mesh_terms":["Adult","Hypomethylating Agents","Myelodysplastic Syndromes","Hematopoietic Stem Cell Transplantation","Risk Factors","Retrospective Studies"],"publication_types":["Randomized Controlled Trial","Case Reports","Editorial"]},{"pmid":37734317,"title":"Venetoclax-based regimens followed by allogeneic stem cell transplant in elderly patients with AML","authors":["Trinh PQ","Andre F","Quintana RC","Eriksson VL"],"journal":"Haematologica","publication_year":2026,"doi":"10.1182/blood.2026.859","mesh_terms":["Survival Analysis","Leukemia, Myeloid, Acute","Disease-Free Survival","Hematopoietic Stem Cell Transplantation","Male"],"publication_types":["Case Reports"]},{"pmid":37401460,"title":"Allogeneic transplantation for therapy-related MDS: outcomes and predictors","authors":["Garcia-Lerma JF","Strand NR","Quintana RC"],"journal":"Transplantation and Cellular Therapy","publication_year":2026,"doi":"10.3324/blood.2026.747","mesh_terms":["Hypomethylating Agents","Disease-Free Survival","Hematopoietic Stem Cell Transplantation","Middle Aged","Myelodysplastic Syndromes","Female"],"publication_types":["Practice Guideline"]},{"pmid":39135982,"title":"Outcomes of pediatric ALL patients undergoing matched unrelated donor transplant","authors":["Brahmer J","DeSimone PL","Lefebvre JP","Sundararajan KP","Garcia-Lerma JF"],"journal":"The Lancet Haematology","publication_year":2025,"doi":"10.1056/blood.2025.571","mesh_terms":["Risk Factors","Adult","Retrospective Studies","Precursor Cell Lymphoblastic Leukemia-Lymphoma"],"publication_types":["Clinical Trial","Editorial","Randomized Controlled Trial"]},{"pmid":36774457,"title":"Real-world outcomes of immune checkpoint inhibitors in NSCLC: a population-based analysis","authors":["Robert C","Mendelsohn AR","Brahmer J"],"journal":"Cancer","publication_year":2025,"mesh_terms":["Carcinoma, Non-Small-Cell Lung","Female","Risk Factors"],"publication_types":["Practice Guideline","Case Reports"]},{"pmid":33884933,"title":"Inotuzumab ozogamicin in pre-transplant MRD-positive B-cell ALL","authors":["Quintana RC","Erdogan SM","Reck M","Mehrotra DV","Tolaney S","Curigliano G"],"journal":"Leukemia","publication_year":2025,"mesh_terms":["Precursor Cell Lymphoblastic Leukemia-Lymphoma","Treatment Outcome","Male","Middle Aged","Adult"],"publication_types":["Editorial"]},{"pmid":39822345,"title":"Osimertinib in EGFR-mutated NSCLC: updated overall survival from FLAURA-2","authors":["DeSimone PL","Mok T","Herbst R","Paz-Ares L","Romero-Castellanos IS"],"journal":"Leukemia","publication_year":2025,"doi":"10.1182/blood.2025.742","mesh_terms":["Immunotherapy","Carcinoma, Non-Small-Cell Lung","Adult","Survival Analysis","Male"],"publication_types":["Randomized Controlled Trial"]},{"pmid":33044726,"title":"Cost-effectiveness of cord blood transplantation in severe aplastic anemia","authors":["Yamaguchi HK","Rugo H","Bjornsson EH","Quintana RC"],"journal":"Blood","publication_year":2025,"doi":"10.3324/blood.2025.719","mesh_terms":["Quality-Adjusted Life Years","Survival Analysis","Adult","Treatment Outcome"],"publication_types":["Case Reports"]},{"pmid":37265678,"title":"Donor lymphocyte infusion for post-transplant relapse in AML: a retrospective multicenter analysis","authors":["Mendelsohn AR","Saura C","Petrov AN","Kennedy BR"],"journal":"Biology of Blood and Marrow Transplantation","publication_year":2025,"doi":"10.1182/blood.2025.925","mesh_terms":["Risk Factors","Female","Disease-Free Survival","Middle Aged","Hematopoietic Stem Cell Transplantation","Disease-Free Survival"],"publication_types":["Review","Clinical Trial"]},{"pmid":31648290,"title":"Allogeneic transplantation for therapy-related MDS: outcomes and predictors","authors":["Erdogan SM","Albright JN","Kowalczyk MA"],"journal":"British Journal of Haematology","publication_year":2025,"doi":"10.1182/blood.2025.894","mesh_terms":["Retrospective Studies","Male","Disease-Free Survival","Risk Factors","Survival Analysis","Female"],"publication_types":["Clinical Trial","Journal Article","Practice Guideline"]},{"pmid":38093052,"title":"Venetoclax-based regimens followed by allogeneic stem cell transplant in elderly patients with AML","authors":["Whitfield TG","Yamaguchi HK","Saura C"],"journal":"Blood Advances","publication_year":2025,"doi":"10.1056/blood.2025.369","mesh_terms":["Hematopoietic Stem Cell Transplantation","Treatment Outcome","Disease-Free Survival","Leukemia, Myeloid, Acute","Risk Factors"],"publication_types":["Meta-Analysis","Journal Article"]},{"pmid":38758766,"title":"Budget impact of expanded cord blood cell therapy in adult allogeneic transplantation","authors":["Kennedy BR","Modi S","Erdogan SM"],"journal":"Transplantation and Cellular Therapy","publication_year":2025,"doi":"10.1182/blood.2025.151","mesh_terms":["Survival Analysis","Middle Aged","Risk Factors","Quality-Adjusted Life Years"],"publication_types":["Journal Article"]},{"pmid":31462528,"title":"Pediatric severe aplastic anemia: a multicenter retrospective study of cord blood transplantation outcomes","authors":["Aldridge TL","Hassan-Ali ZF","Tolaney S","Mok T"],"journal":"Blood Advances","publication_year":2025,"doi":"10.3324/blood.2025.709","mesh_terms":["Immunosuppression Therapy","Female","Male","Retrospective Studies"],"publication_types":["Randomized Controlled Trial","Case Reports"]},{"pmid":35017766,"title":"CAR-T versus autologous transplant in relapsed diffuse large B-cell lymphoma","authors":["Reck M","Garcia-Lerma JF","Curigliano G","Vassallo GR"],"journal":"Journal of Clinical Oncology","publication_year":2025,"doi":"10.1200/blood.2025.057","mesh_terms":["Adult","Treatment Outcome","Retrospective Studies"],"publication_types":["Letter"]},{"pmid":32593629,"title":"Gene therapy versus allogeneic transplantation in severe sickle cell disease: comparative outcomes","authors":["Tolaney S","Albright JN","Saura C","Rosenthal EG","Garassino MC","Rizvi N","Cortes J","Fallon-Reilly KP"],"journal":"Cancer","publication_year":2025,"doi":"10.1056/blood.2025.655","mesh_terms":["Disease-Free Survival","Retrospective Studies","Male","Survival Analysis"],"publication_types":["Journal Article"]},{"pmid":35150296,"title":"Autologous stem cell transplant followed by lenalidomide maintenance in multiple myeloma","authors":["Tatum CD","Ramachandran PV","Petrov AN","Saura C","Holloway TJ"],"journal":"Blood Advances","publication_year":2025,"doi":"10.1200/blood.2025.486","mesh_terms":["Survival Analysis","Risk Factors","Male","Retrospective Studies","Hematopoietic Stem Cell Transplantation","Disease-Free Survival"],"publication_types":["Letter","Review"]},{"pmid":31927915,"title":"Pre-transplant hypomethylating agent therapy in higher-risk MDS","authors":["Cortes J","Reck M","Garassino MC","Erdogan SM","Rugo H","Saura C"],"journal":"Blood","publication_year":2025,"mesh_terms":["Retrospective Studies","Survival Analysis","Myelodysplastic Syndromes"],"publication_types":["Letter","Meta-Analysis"]},{"pmid":35483153,"title":"Measurable residual disease at transplant predicts relapse in patients with acute myeloid leukemia","authors":["Hassan-Ali ZF","Reck M","Rugo H","Kowalczyk MA","Borghaei H","Okeke CA","Herbst R","Saura C"],"journal":"Annals of Oncology","publication_year":2025,"doi":"10.1056/blood.2025.398","mesh_terms":["Male","Treatment Outcome","Disease-Free Survival","Middle Aged","Female","Leukemia, Myeloid, Acute"],"publication_types":["Letter","Review"]},{"pmid":37053575,"title":"Measurable residual disease at transplant predicts relapse in patients with acute myeloid leukemia","authors":["Mehrotra DV","Kowalczyk MA","Halverson MJ"],"journal":"The Lancet Haematology","publication_year":2025,"mesh_terms":["Disease-Free Survival","Disease-Free Survival","Middle Aged","Risk Factors"],"publication_types":["Practice Guideline"]},{"pmid":33498337,"title":"Cytogenetic risk stratification predicts post-transplant outcomes in MDS","authors":["Kowalczyk MA","Halverson MJ","Curigliano G","Modi S","Saura C"],"journal":"New England Journal of Medicine","publication_year":2025,"doi":"10.1182/blood.2025.086","mesh_terms":["Disease-Free Survival","Risk Factors","Female"],"publication_types":["Journal Article"]},{"pmid":39943099,"title":"Blinatumomab as a bridge to transplant in Philadelphia chromosome-positive ALL","authors":["Hawthorne LR","DeSimone PL","Kennedy BR","Castellano FP","Trinh PQ","Fallon-Reilly KP","Sandoval-Vega LF"],"journal":"Leukemia","publication_year":2025,"doi":"10.1016/blood.2025.890","mesh_terms":["Female","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Male","Risk Factors","Disease-Free Survival"],"publication_types":["Meta-Analysis","Review"]},{"pmid":36801748,"title":"Outcomes of cord blood transplantation in severe aplastic anemia after failed immunosuppressive therapy","authors":["Ramachandran PV","Petrov AN","Mendelsohn AR","Hassan-Ali ZF","Yi MJ","Sundararajan KP"],"journal":"Bone Marrow Transplantation","publication_year":2025,"doi":"10.1182/blood.2025.673","mesh_terms":["Immunosuppression Therapy","Female","Adult"],"publication_types":["Meta-Analysis"]},{"pmid":33246510,"title":"Blinatumomab as a bridge to transplant in Philadelphia chromosome-positive ALL","authors":["Okeke CA","Albright JN","Reck M","Robert C"],"journal":"Annals of Oncology","publication_year":2025,"doi":"10.1182/blood.2025.665","mesh_terms":["Disease-Free Survival","Hematopoietic Stem Cell Transplantation","Risk Factors","Male"],"publication_types":["Randomized Controlled Trial"]},{"pmid":32154076,"title":"Pre-transplant hypomethylating agent therapy in higher-risk MDS","authors":["Hassan-Ali ZF","Vassallo GR","Mehrotra DV","Rugo H","Erdogan SM","Tagavi RM","Modi S"],"journal":"Annals of Oncology","publication_year":2025,"doi":"10.1182/blood.2025.324","mesh_terms":["Hematopoietic Stem Cell Transplantation","Retrospective Studies","Treatment Outcome","Disease-Free Survival","Male","Female"],"publication_types":["Clinical Trial","Review"]}]}